Singulair and Dermatitis atopic aggravated - a phase IV clinical study of FDA data

Summary:

Dermatitis atopic aggravated is reported as a side effect among people who take Singulair (montelukast sodium), especially for people who are female, 10-19 old, have been taking the drug for < 1 month also take Dupixent, and have Eczema.

The phase IV clinical study analyzes which people have Dermatitis atopic aggravated when taking Singulair. It is created by eHealthMe based on reports of 125,532 people who have side effects when taking Singulair from the FDA, and is updated regularly.

What is Singulair?

Singulair has active ingredients of montelukast sodium. It is often used in asthma. eHealthMe is studying from 129,752 Singulair users. Check the latest studies of Singulair.

What is Dermatitis atopic aggravated?

Dermatitis atopic aggravated (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder) is found to be associated with 617 drugs and 179 conditions by eHealthMe. Check the latest studies of Dermatitis atopic aggravated.

On Jul, 08, 2026

125,532 people reported to have side effects when taking Singulair.
Among them, 380 people (0.3%) have Dermatitis atopic aggravated.

Could Singulair cause Dermatitis atopic aggravated?

Among these 380 people:

How long have people been on Singulair when they have Dermatitis atopic aggravated? *

Click here to view more results

What is the gender of people who have Dermatitis atopic aggravated when taking Singulair? *

Click here to view

What is the age of people who have Dermatitis atopic aggravated when taking Singulair? *

Click here to view more results

* Approximation only. Some reports may have incomplete information.

Do you take Singulair and have Dermatitis atopic aggravated?

- Check whether Dermatitis atopic aggravated is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Singulair:

Singulair (129,752 reports)

Dermatitis atopic aggravated treatments and more:

Dermatitis atopic aggravated (31 reports)

How severe was Dermatitis atopic aggravated and when was it recovered:

Dermatitis atopic aggravated in Singulair

Expand to all the drugs that have ingredients of montelukast sodium:

Dermatitis atopic aggravated and drugs with ingredients of montelukast sodium (914 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Singulair:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Dermatitis atopic aggravated:

Dermatitis atopic aggravated (617 drugs)

Browse all the conditions that are associated with Dermatitis atopic aggravated:

Dermatitis atopic aggravated (179 conditions)

Related publications that referenced our studies

Das S, Mondal S, Dey JK, Bandyopadhyay S, Saha I, Tripathi SK, "A case of montelukast induced hypercholesterolemia, severe hypertriglyceridemia and pancreatitis", Journal of Young Pharmacists, 2013 Jun .
Das S, Mondal S, Dey JK, Bandyopadhyay S, Saha I, Tripathi SK, "A case of montelukast induced hypercholesterolemia, severe hypertriglyceridemia and pancreatitis", Journal of Young Pharmacists, 2013 Jun .

How the study uses the data?

The study uses data from the FDA. It is based on montelukast sodium (the active ingredients of Singulair) and Singulair (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.